<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946553</url>
  </required_header>
  <id_info>
    <org_study_id>MICRORIN</org_study_id>
    <nct_id>NCT03946553</nct_id>
  </id_info>
  <brief_title>The Dysbiosis of the Intestinal Microbiota in Individuals With Allergic Rhinitis (MICRORIN)</brief_title>
  <acronym>MICRORIN</acronym>
  <official_title>The Dysbiosis of the Intestinal Microbiota in Individuals With Allergic Rhinitis: an Observational Study (MICRORIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technological Centre of Nutrition and Health, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technological Centre of Nutrition and Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biopolis S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technological Centre of Nutrition and Health, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis (AR) is triggered by environmental allergens such as pollen and mites, and
      is associated with several symptoms such as itching and nasal congestion, sneezing or tearing
      and redness of the eyes. RA can affect patients life quality who suffer it, reducing the
      quality of sleep and cognitive function, causing irritability and fatigue and, consequently a
      decrease in work performance.

      Because the existing pharmacological treatments for RA are not entirely effective, it is of
      interest to find other means to enhance the effects of these drugs and decrease more
      effectively the signs and symptoms associated with RA. In this context, RA has been related
      to an alteration of the intestinal microbiota (MI).However, there is a need to characterize
      in detail the MI of individuals who suffer RA.

      The main objective of the present study is to characterize the MI of individuals with RA,
      compared with people without RA. In addition, the secondary objective is to study the
      association between characteristics of the MI of individuals with RA and different
      immunological markers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Intestinal microbiota characterization</measure>
    <time_frame>At Day 1</time_frame>
    <description>Taxonomic identification of the intestinal microbiota of the participants by sequencing the fecal DNA samples using MiSeq platform of Illumina in combination with 250/300PE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers in blood</measure>
    <time_frame>At Day 1</time_frame>
    <description>Quantification of the pro-inflammatory markers Interleuquin (IL)-6 and TNFalpha and of the anti-inflammatory marker IL-10 in blood by ELISA kits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological markers in faeces</measure>
    <time_frame>At Day 1.</time_frame>
    <description>Quantification of Immunoglobulin (Ig) A levels in faeces by ELISA kit as a marker of intestinal inflammatory response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological markers in blood</measure>
    <time_frame>At Day 1.</time_frame>
    <description>Quantification of IgE by Phadiatop adults.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Allergic Rhinitis Group</arm_group_label>
    <description>Individuals with allergic rhinitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Individuals without allergic rhinitis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      fecal samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In the study will be two types of populations. A population with allergic rhinitis and a
        population without allergic rhinitis and that serves as control group.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Allergic Rhinitis population:

          1. Men and women over 18 years of age.

          2. Sign the informed consent.

          3. Present, according to the ARIA classification (Allergic Rhinitis ans its impact on

             Asthma), two or more of the following symptoms for more than one hour a day:

               -  Aqueous rhinorrhea.

               -  Sneezing, especially paroxysmal.

               -  Nasal obstruction.

               -  Itching or nasal itch.

               -  Conjunctivitis (itching, lacrimation or redness).

          4. Individuals presenting Persistent or Perennial type of RA, in which signs are present:

               -  More than four days a week.

               -  And for more than four consecutive weeks.

        Exclusion Criteria Allergic Rhinitis population:

          1. Purulent Rhinorrhea.

          2. Being pregnant.

          3. Be in breastfeeding period.

          4. Having diabetes (glucose ≥ 126 mg/dL).

          5. BMI values &gt; 30 kg/m^2.

          6. Present dyslipidemia (LDL cholesterol ≥ 189 mg/dL and/or triglycerides ≥ 350 mg/dL).

          7. Systolic Blood Pressure ≥ 160 mmHg and/or Diastolic Blood Pressure ≥ 100 mmHg.

          8. Have received treatment with antibiotics 30 days before the start of the study.

          9. Have received treatment with corticosteroids 30 days before the start of the study.

         10. Individuals who usually intake prebiotics and/or probiotics supplements 30 days before
             the start of the study.

        Inclusion Criteria Control population:

          1. Men and women over 18 years of age.

          2. Sign the informed consent.

          3. Do not present any signs or symptoms of RA.

        Exclusion Criteria Control population:

          1. Being pregnant.

          2. Be in breastfeeding period.

          3. Having diabetes (glucose ≥ 126 mg/dL).

          4. BMI values &gt; 30 kg/m^2.

          5. Present dyslipidemia (LDL cholesterol ≥ 189 mg/dL and/or triglycerides ≥ 350 mg/dL).

          6. Systolic Blood Pressure ≥ 160 mmHg and/or Diastolic Blood Pressure ≥ 100 mmHg.

          7. Have received treatment with antibiotics 30 days before the start of the study.

          8. Have received treatment with corticosteroids 30 days before the start of the study.

          9. Individuals who usually intake prebiotics and/or probiotics supplements 30 days before
             the start of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Solà, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTNS (Eurecat_Reus)/HUSJR. Reus, Tarragona, Spain.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosa M Valls, PhD</last_name>
    <phone>0034 636944723</phone>
    <email>estudis@ctns.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Crescenti, PhD</last_name>
    <phone>+34977770958</phone>
    <email>anna.crescenti@eurecat.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Technological Centre of Nutrition and Health (Eurecat-Reus)</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosa Valls, PhD</last_name>
      <phone>+34 636 944 723</phone>
      <email>estudis@ctns.cat</email>
    </contact>
    <contact_backup>
      <last_name>Anna Crescenti, PhD</last_name>
      <phone>+34 977 77 09 58</phone>
      <email>anna.crescenti@eurecat.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://eurecat.org</url>
    <description>Technological Centre of Nutrition and Health. Eurecat_Reus.</description>
  </link>
  <link>
    <url>http://biopolis.es</url>
    <description>Biopolis S.L.</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intestinal microbiota</keyword>
  <keyword>immunological markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

